| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于对外投资设立香港全资子公司的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资基本情况 重庆正川医药包装材料股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日召开第四届董事会第二十二次会议、第四届监事会第十五次会议，审议通过了 《关于对外投资设立香港全资子公司的议案》，同意公司投资 50 万美元（或等额 的其他货币）在香港设立全资子公司。具体内容详见公司于 2025 年 6 月 5 日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体上披露的《关于对 外投资设立香港全资子公司的公告》（公告编号：2025-032）。 二、对外投资进展情况 近日，公司已完成香港子公司的注册登记手续，并取得了当地行政主管部门 签发的《公司注册证明书》及《商业登记证》，相关 ...

Core Viewpoint - Zhengchuan Co., Ltd. has successfully completed the registration procedures for its Hong Kong subsidiary and has obtained the necessary certificates from local authorities [1] Group 1 - The company has received the "Company Registration Certificate" and "Business Registration Certificate" from the local administrative authority [1]

Core Viewpoint - Zhengchuan Co., Ltd. has successfully registered its wholly-owned subsidiary, Zhengchuan International (Hong Kong) Limited, in Hong Kong, marking a strategic expansion into the international market [1] Group 1 - The investment amount for the establishment of the subsidiary is $500,000 or equivalent in other currencies [1] - The registered address of the subsidiary is RM H2, 4/F Century Ind CTR 33-35 Au Pui Wan St Fotan Sha Tin Hong Kong [1] - The company has obtained the Company Registration Certificate and Business Registration Certificate, with the registration certificate number being 79109077 and the business registration number being 79109077-000-11-25-8 [1] Group 2 - The effective date of the registration is November 7, 2025 [1]

Core Viewpoint - The company, Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd., has approved the use of idle self-owned funds for cash management to enhance fund utilization efficiency and increase returns for the company and its shareholders [2][3][14]. Cash Management Overview - The purpose of cash management is to ensure the safety of funds while not affecting the company's daily operations, thereby improving fund utilization efficiency [3]. - The total investment amount for this cash management initiative is 50 million RMB [4]. - The funds for this cash management are entirely sourced from idle self-owned funds [5]. Cash Management Product Details - The cash management product is a structured deposit from Chongqing Bank, with an investment amount of 50 million RMB and a term of 57 days [7]. - The product offers a guaranteed minimum return of 1.15%, with potential floating returns of 0.8% or 1.0% based on specific conditions related to the EUR/USD exchange rate [8]. Risk Control Measures - The company will select investment products that are high in safety, good in liquidity, and of medium to low risk, including bank wealth management products, securities firm wealth management products, trust wealth management products, structured deposits, notice deposits, and large certificates of deposit [6][9]. - Independent directors have the authority to supervise and inspect the use of funds, and the company will conduct timely analysis and monitoring of cash management progress [10]. Impact on the Company - The company does not have significant overdue debts while engaging in large-scale wealth management products, ensuring that cash management will not affect normal operational cash flow or the development of core business [13][14].

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2025-072 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 履行的审议程序：重庆正川医药包装材料股份有限公司（以下简称"公 司"）于2025年6月4日召开了第四届董事会第二十二次会议、第四届监事会第十 五次会议，审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公 司使用单日最高余额不超过人民币30,000万元的闲置自有资金进行现金管理，以 上资金额度在董事会审议通过之日起12个月内可以循环滚动使用。具体内容详见 公司于2025年6月5日在上海证券交易所网站（www.sse.com.cn）及指定信息披露 媒体上披露的《关于使用闲置自有资金进行现金管理的公告》（公告编号： 2025-031）。 一、本次现金管理概况 （一）目的 在不影响公司日常经营活 ...

Core Viewpoint - Ningbo Suobao Protein Technology Co., Ltd. reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong growth in the soybean protein market driven by rising consumer demand for health and safety in food products [1][2]. Group 1: Financial Performance - The company achieved operating revenue of 1.24 billion yuan, a year-on-year increase of 7.37% [1] - Net profit attributable to shareholders reached 147 million yuan, reflecting a substantial year-on-year growth of 60.00% [1] - In Q3 alone, operating revenue was 466 million yuan, up 21.75% year-on-year, while net profit for the quarter was 49.26 million yuan, marking a remarkable increase of 135.87% [1] Group 2: Business Operations - Suobao Protein specializes in the research, production, and sales of non-GMO soybean protein products, having established a comprehensive deep processing industry chain for non-GMO soybeans [1] - The main products include soybean isolate protein, soybean concentrate protein, textured protein, soybean dietary fiber, and non-GMO soybean oil [1] - The company is actively expanding its international market presence while consolidating its domestic market, enhancing brand recognition and influence [2] Group 3: Industry Trends - There is a growing consumer focus on environmental and health issues, leading to increased demand for organic, green, functional, and health foods globally [1] - Soybean protein is widely used in various sectors, including plant-based meat, meat products, snacks, health products, nutritional supplements, pet food, and bio-fermentation, indicating a broad market development potential [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | 重庆正川医药包装材料股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 会议召开时间：2025 年 11 月 18 日(星期二)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日(星期二)至 11 月 17 日(星期一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zczq@cqzcjt.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 重庆正川医药包装材料股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解 公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 18 ...

Core Viewpoint - Zhengchuan Co., Ltd. reported a decline in both revenue and net profit for the third quarter, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 134 million yuan in the third quarter, representing a year-on-year decrease of 9.98% [1] - The net profit attributable to shareholders was 2.251 million yuan, down 70.23% compared to the same period last year [1] - Basic earnings per share were reported at 0.02 yuan [1]

| | | 重庆正川医药包装材料股份有限公司 第五届董事会第二次会议决议公告 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）及指定信 息披露媒体上披露的《重庆正川医药包装材料股份有限公司 2025 年第三季度报 告》。 特此公告。 重庆正川医药包装材料股份有限公司董事会 本次会议由董事长邓勇先生召集和主持，公司高级管理人员及相关人员列席 了会议。本次会议的召集、召开和表决程序均符合《公司法》等法律、行政法规 以及《公司章程》《公司董事会议事规则》的有关规定，会议的召集、召开合法 有效。 二、董事会会议审议情况 会议审议通过了《关于公司 2025 年第三季度报告的议案》 公司 2025 年第三季度报告的编制程序符合法律、法规、《公司章程》和公司 管理制度的各项规定；本次季度报告的内容真实、准确、完整，不存在任何虚假 记载、误导性陈述或者重大遗漏，报告客观地反映了公司 2025 年第三季度的财 务及经营状况。 表决结果：9 票同意、0 票反对、0 票弃权。 本议案已经公司第五届董事会审计委员会第二次会议审议通过。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重 ...

Group 1 - The core viewpoint of the news is that Zhengchuan Co., Ltd. reported a significant decline in its third-quarter performance for 2025, with revenue and net profit both decreasing substantially compared to the previous year [1] Group 2 - Zhengchuan Co., Ltd. reported approximately 458 million yuan in revenue for the first three quarters of 2025, representing a year-on-year decrease of 24.92% [1] - The net profit attributable to shareholders of the listed company was approximately 16.34 million yuan, a year-on-year decrease of 68.54% [1] - The basic earnings per share were 0.11 yuan, down 67.65% year-on-year [1] Group 3 - As of the report, Zhengchuan Co., Ltd. has a market capitalization of 3 billion yuan [2]